Abstract
Blood coagulation tests done in 38 women bearing subdermal implants of megestrol acetate as a contraceptive after 14 to 43 months continuous treatment. A group of 12 untreated women of similar age and parity was used as control. Platelet count, clotting time, prothrombin time, partial thromboplastin time, prothrombin consumption test, thromboplastin generation time, euglobulin lysis time, fibrinogen, factors II, V, VII-X, X and VIII, and platelet adhesiveness were determined during the follicular phase of the cycle. All tests showed normal values and no significant differences were found between the groups. It was concluded that continuous, systemic and long-term administration of megestrol acetate does not lead to blood coagulation disorders.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
